R&D News | pharmaphorum

News

Novartis gets a win in chronic hives, setting up filings

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for refractory chronic spontaneous urticaria (CSU) for many years, but its efforts to find a su

News

Arcus and Gilead drop A2R drug for prostate cancer

Arcus and Gilead Sciences have decided not to continue the development of their A2 receptor antagonist etrumadenant in castration-resistant prostate cancer (CRPC) after an

News

Bayer pulls plug on respiratory drug PEG-ADM

Bayer revealed in its second-quarter results update this morning that it has stopped the development of adrenomedullin pegol (PEG-ADM), which had reached phase 2 for the t

News

Advantage Novo Nordisk in battle of weight-loss drugs

Novo Nordisk has claimed an edge in the increasingly competitive obesity therapy category after reporting that its Wegovy therapy reduced cardiovascular outcomes by 20% in

News

Astellas adds to cell therapy drive with Poseida deal

Astellas has added another programme to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumours.

News

Nektar says Lilly got it wrong on eczema drug rezpeg

Nektar Therapeutics says that Eli Lilly made a big mistake when it reported data on a pair of phase 1b trials of its rezpegaldesleukin drug in atopic dermatitis and psoria

Novartis gets a win in chronic hives, setting up filings

Arcus and Gilead drop A2R drug for prostate cancer

Bayer pulls plug on respiratory drug PEG-ADM

Advantage Novo Nordisk in battle of weight-loss drugs

Astellas adds to cell therapy drive with Poseida deal

Nektar says Lilly got it wrong on eczema drug rezpeg

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks